International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7690330
Original Article
Study of Pancreatic Enzymes in Chronic Kidney Disease Patients
Published
March 2, 2023
Abstract
Background – Elevation in serum levels of amylase and lipase in the absence of pancreatitis, in CKD patients. Aim – Evaluation of pancreatic enzymes level in CKD patients. Materials and methods – 135 patients were included and they were classified in stage I - V of CKD according to KDIGO(Kidney Disease Improving Global Outcome) guidelines and their serum amylase and lipase levels were evaluated. Results – We included 135 patients, in the age group of 30-60 yrs. Among 135 patients, 110 patients were divided in stages from I to V of CKD (Chronic Kidney Disease) as per KDIGO (Kidney Disease Improving Global Outcome), and 25 patients were divided in Pre HD and Post HD group. The serum amylase and lipase were significantly higher in CKD patients as the stage progresses form I to V (p= 0.000). In Pre HD and Post HD group of patients mean value of serum amylase and serum lipase were significantly higher in Post HD group in comparison to Pre HD (p=0.000) Conclusion – Our study done among 135 patients indicate that there was certain amount of retention of pancreatic enzyme in CKD patients due to decreased excretion by kidneys. And patients on HD had elevated level of these enzymes in Post HD state which was probably due to increase in lipoprotein lipase from endothelial cells of capillaries and we were measuring Total lipase in serum. Secondly due to hemoconcentration which occurs during HD by removal of fluid from body. Hence levels of total amylase and lipase increases in serum after hemodialysis.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
994 Views
397 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved